Dysregulation of microRNAs (miRNAs) is acknowledged in human cutaneous squamous cell carcinoma (cSCC). We hereby evaluated the ability of miR-216b (miR-216b) to impact human cSCC. cSCC tissues with corresponding adjacent normal tissues were collected from 40 patients diagnosed with cSCC where the expression pattern of miR-216b and targeting protein for Xenopus kinesin-like protein 2 (TPX2) was determined by quantitative reverse transcriptase polymerase chain reaction (qRT-PCR) and western blot analysis. A431 cells were transfected with miR-216b mimic, miR-216b inhibitor, or short interfering RNA against TPX2 to evaluate cell proliferation, invasion, migration, and apoptosis using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay, scratch test, Transwell assay, and flow cytometry. TPX2 was highly expressed in cSCC tissues while miR-216b was poorly expressed in association with tumor differentiation, lymph node metastasis, and tumor node metastasis staging in patients with cSCC. In response to overexpressed miR-216b or silenced TPX2, cSCC cell proliferation, invasion, and migration were suppressed and apoptosis was stimulated, along with activated p53 signaling. Thus, upregulated miR-216b was capable of promoting apoptosis and inhibiting proliferation, invasion, and migration of cSCC cells by downregulating TPX2 through activation of the p53 signaling, highlighting a novel biomarker for novel treatment modalities against cSCC.

INTRODUCTION

Cutaneous squamous cell carcinoma (cSCC) is an epidermal keratinocyte originating from skin tumors. Statistics have indicated that males are more susceptible to cSCC than their female counterparts, with a substantially underestimated disease burden due to diverse primaries over time. Epidemiological studies have illustrated the association of several physical and chemical factors with cSCC incidence, such as chronic sun exposure, ionizing radiation and arsenic, psoralens, and coal tar products. The conventional therapeutic modalities for cSCC are more susceptible to cSCC than their female counterparts, with a 1-year survival rate of 44%–56%. Numerous studies have demonstrated that microRNAs (miRNAs) play various roles in cancer development, invasion, diagnosis, prognosis, and treatment. miR-216b is located at the chromosome 2p16.1 and acts as a tumor suppressor in multiple types of cancers. The targeting protein for Xenopus kinesin-like protein 2 (TPX2) is a cell-cycle-related human protein and related to cell cycle. Tumor cell growth may be inhibited by blocking TPX2 expression, which highlights TPX2 as a potential target for antitumor treatment. The upregulation of TPX2 has been elucidated in different forms of malignant tumors, however, few studies have explored its expression profile and functional relevance in cSCC. TPX2-p53 regulatory circuit mediates cell proliferation and invasion in bladder cancer. The p53 signaling is able to trigger cell-cycle exit, rectify DNA damage, and induce apoptosis. Loss of p53 function is a common finding in cancers, whether by mutations in p53 itself or through perturbations in signaling. However, unlike in other solid tumors, p53 mutations are early and prevalent in cSCC. A study by Allegra et al. has reported that miR-216b is negatively regulated in blood cancers. Moreover, it has been suggested that miR-216b can upregulate p53 expression. Given the aforementioned studies, we hypothesized the involvement of miR-216b in cSCC, which may implicate the regulation of TPX2 and the p53 signaling.

RESULTS

TPX2 Protein Is Upregulated in cSCC Tissues

Immunohistochemistry results showed that TPX2 was primarily localized in the nucleus as brownish yellow particles (Figure 1A). The positive expression level of TPX2 in cSCC tissues was 82.50%, which was higher than that in adjacent normal tissues (7.50%) (p < 0.05, Figure 1B). These findings demonstrated an elevated TPX2 expression in cSCC tissues.

miR-216b Is Expressed at Low Levels in cSCC Tissues

In comparison to the adjacent normal tissues, miR-216b was downregulated in cSCC tissues. The p53 signaling-related factors, p53, p21, and MDM2, cell proliferation marker proliferating cell nuclear

E-mail: 397896975@qq.com
antigen (PCNA), and apoptosis-related protein B cell lymphoma-2 (bcl-2)/bcl-2 associated protein X (bax) levels were examined by conducting quantitative reverse transcriptase polymerase chain reaction (qRT-PCR) and western blot analysis. The results indicated that the mRNA (Figure 2A) and protein levels (Figures 2B and 2C) of TPX2, MDM2, and PCNA were elevated in cSCC tissues compared to adjacent normal tissues, whereas miR-216b, p53, and p21 levels decreased and bcl-2/bax level was elevated (both p < 0.05). Conjointly, miR-216b was poorly expressed in cSCC tissues.

miR-216b Is Negatively Correlated with the Tumor Malignancy in Patients with cSCC
The correlation between the miR-216b expression and clinicopathological features of patients with cSCC was analyzed (Table 1). Expression of miR-216b was not related to patient age, gender, or tumor size but significantly downregulated in patients with lower degrees of differentiation, lymph node metastasis (LNM), and stage III + IV, indicating that miR-216b expression was closely associated with and the degree of differentiation, LNM, and tumor, node, and metastasis (TNM) staging in patients with cSCC.

TPX2 Is a Direct Target Gene of miR-216b
The prediction results available from microRNA.org revealed that miR-216b could bind to the TPX2 3’ untranslated region (3’ UTR). Dual luciferase reporter gene assay was performed for verification and the results showed that miR-216b mimic exerted no significant effect on luciferase activity in the TPX2 mutant (TPX2-Mut)/miR-216b mimic group but significantly inhibited luciferase activity in the TPX2-wild-type (TPX2-WT)/miR-216b mimic group (p < 0.05), indicating the ability of miR-216b to target TPX2 (Figure 3A). To further explore the underlying regulatory mechanism, we overexpressed miR-216b by miR-216b mimic and silenced using miR-216b inhibitor in A431 cells, followed by TPX2 expression quantification using western blot analysis (Figures 3B and 3C). It was found that TPX2 expression was significantly diminished in the presence of miR-216b mimic but elevated in response to miR-216b inhibitor. Altogether, the aforementioned findings demonstrated that miR-216b targeted and negatively regulated TPX2.

miR-216b Participates in Regulation of cSCC Proliferation- and Apoptosis-Related Genes through Targeting TPX2
Subsequently, qRT-PCR and western blot analysis were conducted to determine the expression pattern of p53 signaling-related factors (p53, p21, and MDM2), cell proliferation marker PCNA, and apoptosis-related protein bcl-2/bax levels. Results showed that the blank and negative control (NC) groups did not reveal a significant difference (p > 0.05). However, compared to the NC group, the miR-216b mimic group presented with increased expression levels of miR-216b, p53, and p21 along with decreased levels of TPX2, MDM2, PCNA, and bcl-2/bax (p < 0.05). The opposite changing tendency was observed in the miR-216b inhibitor group, while the silenced (si)-TPX2 (si-TPX2) group showed an identical trend to the miR-216b mimic group (p < 0.05), except for insignificant changes in miR-216b expression (p > 0.05). In comparison to the miR-216b inhibitor group, the miR-216b inhibitor + si-TPX2 group displayed higher levels of p53 and p21, as well as lower levels of TPX2, MDM2, PCNA, and bcl-2/bax (p < 0.05) (Figures 4A–4F). To conclude, miR-216b was proved to inhibit cell proliferation and stimulate cell apoptosis by downregulating TPX2 via the p53 signaling.
Overexpression of miR-216b Reduces cSCC Cell Viability, Migration, and Invasion by Suppressing TPX2

3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay (Figure 5A), scratch test (Figures 5B and 5C), and Transwell assay (Figures 5D and 5E) were conducted to further explore the effect of the miR-216/TPX2 axis on cSCC cell viability, migration, and invasion, respectively. MTT assay (Figure 5A) showed that, compared to the blank group, no significant differences were witnessed in the NC group (p > 0.05). It was observed that cell viability, migration, and invasion were markedly suppressed in the miR-216b mimic and si-TPX2 groups (p < 0.05) but enhanced in the miR-216b inhibitor group (p < 0.05). More significant results were detected in the miR-216b inhibitor + si-TPX2 group compared to the miR-216b inhibitor group (p < 0.05). The results elucidated that overexpressed miR-216b exerted inhibitory effects on cSCC cell viability, migration, and invasion by downregulating TPX2.

Overexpressed miR-216b and Silenced TPX2 Inhibit Cell-Cycle Entry and Promote Apoptosis in cSCC Cells

Lastly, flow cytometry was performed for investigating the effects of miR-216b and TPX2 on cell-cycle distribution and apoptosis. Results (Figure 6) showed no notable differences in cell-cycle distribution and apoptosis between the blank and NC groups (p > 0.05). However, the miR-216b mimic and si-TPX2 groups showed a prolonged G0/G1 phase (more cells), a shortened S phase (fewer cells), and stimulated cell apoptosis, yet opposite results were observed in the miR-216b inhibitor group (p < 0.05). In comparison to the miR-216b inhibitor group, the miR-216b inhibitor + si-TPX2 group showed more significant results (p < 0.05). Collectively, upregulated miR-216b affected cSCC cell-cycle distribution and stimulated cell apoptosis through target inhibition of TPX2.

DISCUSSION

cSCC is the second most common skin cancer with increasing incidence, and many cases metastasize to regional lymph nodes or distant organs.18 In this study, we found that miR-216b activated the p53 signaling by inhibiting TPX2, thereby promoting apoptosis and inhibiting the proliferation, invasion, and migration of cSCC cells.

Our findings demonstrated that miR-216b and p53 expressions were decreased, while TPX2 expression was elevated in cSCC tissues. In addition, a correlation was witnessed between the miR-216b level and differentiation, LNM, and TNM staging. Numerous studies have identified the functionality of miR-216b as a tumor suppressor in solid tumors.16,19 Besides, miR-216b expression profile is downregulated in hepatocellular carcinoma (HCC) tissues and is negatively associated with tumor size, portal metastasis, and prognosis after liver resection.20 However, in approximately 50% of HCC patients, the mutations and the loss of the p53 gene are evident, and p53 has been proposed to serve as a cellular gatekeeper for cell development, division, and apoptosis.21 Recent studies have demonstrated that cancer-related MDM2 short isoforms play an important role in mutant p53 degradation, which leads to the stabilization and accumulation of mutant p53 in several tumors.22,23 The p53-MDM2 interaction forms the underlying foundation of p53 dynamics, and several transcription-related factors can regulate p53 activity.24

This study indicated that miR-216b could negatively target TPX2 and stimulate activation of the p53 signaling. The tumor suppressor p53, essentially a transcription factor, serves critically in preventing cells from various cellular stresses, which includes DNA damage and...
oncogene activation. When DNA damage occurs, p53 protein is activated to arrest chromosome replication at a metabolic check point, which facilitates DNA repair. Deficiencies in the p53 pathway activation are fundamentally associated with cell malignancy and tumor development. Pascreau et al. have showed that the novel synthesis of TPX2 is essential for p53 synthesis during oocyte maturation. Kim et al. have showed that miR-216b can intensify senescent-related β-galactosidase staining and enhance p53 and p21 expression and reactive oxygen species production. Furthermore, the negative role of miR-216b in the modulation of p53 is consistent with the aforementioned evidence and the target relationship detected.

Further, overexpression of miR-216b and silencing of TPX2 could facilitate cell apoptosis and consequently inhibit cell proliferation, invasion, and migration. Overexpressed miR-216b may induce decreased growth and clonogenicity and enhance apoptosis in breast cancer cells. Moreover, miR-216b could inhibit poly-ADP-ribose polymerase-1 (PARP1) expression, thus suppressing the DNA repair process, which, in turn, promotes cell apoptosis. TPX2 fundamentally functions as a central mediator in vertebrate cells. TPX2 expression is tightly regulated during all stages of the cell cycle, becomes detectable at the G1-S transit, and disappears upon completion of cytokinesis. In addition, the reactivation of p53 can induce significant apoptosis and allow the eradication of tumor cells in vivo. Datta et al. have found that the replication initiation factor Cdc7 kinase, whose overexpression can contribute to S-phase arrest, is augmented by a gain-of-function mutant p53 in cells. Consistently, our findings showed that, compared to the cells transfected with an miR-216b inhibitor, cells co-transfected with miR-216b inhibitor + siRNA against TPX2 exhibited reduced proliferation, invasion, and migration, amplified apoptosis, and a high proportion of cells progressing from G1 to S phase.

In conclusion, miR-216b regulates the p53 signaling by inhibiting TPX2 leading to impeded cSCC progression, thereby providing a promising therapeutic target for cSCC. Future studies expanding the therapeutic potential of this newly identified target will have important clinical implications.

MATERIALS AND METHODS

Ethical Statements

This study was conducted with approval of the Institutional Review Board of Peking Union Medical College Hospital and in accordance with the declaration of Helsinki. Written informed consent was obtained from each participant.

Table 1. Relationship between the Expression of miR-216b and Clinicopathological Features of Patients with Squamous Cell Carcinoma

| Clinicopathological Features | Expression of miR-216b | n | High (n = 26) | Low (n = 14) | p |
|------------------------------|------------------------|---|--------------|--------------|---|
| Age (year)                   |                        |   |              |              |   |
| <50                          |                        | 17| 13           | 4            |   |
| ≥ 50                         |                        | 23| 13           | 10           | 0.191 |
| Gender                       |                        |   |              |              |   |
| Male                         |                        | 24| 18           | 6            | 0.104 |
| Female                       |                        | 16| 8            | 8            |   |
| Tumor size (cm)              |                        |   |              |              |   |
| <4                           |                        | 16| 10           | 6            | 0.787 |
| ≥ 4                          |                        | 24| 16           | 8            |   |
| Differentiation              |                        |   |              |              |   |
| Poor/undifferentiation       |                        | 21| 9            | 12           | 0.002 |
| Well/moderate differentiation|                        | 19| 17           | 2            |   |
| LNM                          |                        |   |              |              |   |
| Yes                          |                        | 12| 4            | 8            | 0.006 |
| No                           |                        | 28| 22           | 6            |   |
| TNM staging                  |                        |   |              |              |   |
| III + IV                     |                        | 13| 4            | 9            | 0.002 |
| I + II                       |                        | 27| 22           | 5            |   |

The data were expressed as mean ± standard deviation and analyzed by chi-square test.

Figure 3. TPX2 Is Confirmed as a Target Gene of miR-216b

(A) Luciferase activity of the TPX2-WT and TPX2-Mut after transfection determined by dual luciferase reporter gene assay. (B and C) Protein bands and protein levels of TPX2 in A431 cells normalized to GAPDH determined by western blot analysis. Data were expressed as mean ± standard deviation and analyzed by the unpaired t test. *p < 0.05.

www.moleculartherapy.org
Subjects

From February 2013 to December 2016, cSCC tissues (tumor lesions) and adjacent normal tissues (>5 cm away from tumor tissues) were obtained from 40 patients with cSCC (24 males, 16 females, age: 41–82 years, mean age: 57 years) who underwent surgery at the Peking Union Medical College Hospital. None of the patients received any anti-tumor treatment prior to the operation. Patients were included if they met the following criteria: (1) patients provided comprehensive case data; (2) basal cell carcinoma was excluded under the histopathological examination and the liquid-based cytology test; and (3) patients did not manifest with other cutaneous diseases, for example, pathological changes in the lung, liver, or nasopharynx. Exclusion criteria were as follows: (1) inadequate case data of patients; (2) patients were diagnosed with basal cell carcinomas; and (3) patients were diagnosed with cervical cancer, lung cancer, liver cancer, or nasopharyngeal cancer. Tumors were categorized in accordance with the classification of pathological diagnosis and differentiation grade of malignant tumors as follows: undifferentiation, n = 9; poor differentiation, n = 12; moderate differentiation, n = 11; well differentiation, n = 8; and LNM, n = 12. TNM is an internationally recognized protocol for clinical staging classification issued by The Union for International Cancer Control to determine the severity and invasion of tumors objectively. T refers to primary tumor, N refers to lymphatic metastasis, and M refers to distant metastasis. Stage I is determined when tumor cells are limited to the primary site. Stage II is determined when obvious local invasion can be observed with LNM detected in certain areas. Stage III is determined when local invasion or LNM is extensive. Stage IV is determined when tumor cells reveal distant metastasis. LNM, as the most

Figure 4. Overexpressed miR-216b Inhibits Proliferation and Induces Apoptosis through Activation of the p53 Signaling by Downregulating TPX2 in cSCC

(A) miR-216b expression in A431 cells determined by qRT-PCR. (B) mRNA levels of p53, p21, TPX2, and MDM2 in A431 cells determined by qRT-PCR. (C) mRNA levels of proliferation marker PCNA and apoptosis-related factors bcl-2/bax in A431 cells determined by qRT-PCR. (D) Western blots of p53, p21, TPX2, MDM2, PCNA, and bcl-2/bax in A431 cells normalized to GAPDH. (E) Protein expressions of p53, p21, TPX2, MDM2 in A431 cells determined by western blot analysis. (F) Protein expressions of PCNA and bcl-2/bax in A431 cells determined by western blot analysis. Data were expressed as mean ± standard deviation, and data among multiple groups were compared by one-way ANOVA, followed by the Tukey’s post hoc test. *p < 0.05.
common form of metastasis, indicates the symptom when tumor arises from infiltrated tumor cells centering on the lymph gland in the confluence area where the detached infiltrated tumor cells are carried along with lymph after passing through walls of lymphatic vessels.

**Immunohistochemistry**

Formalin (10%)-fixed, paraffin-embedded specimens (4-μm sections) were placed at 60°C for 20 min. Sections were dewaxed (by sequential soaking) in xylene and hydrated in anhydrous alcohol I for 2 min, anhydrous alcohol II for 2 min, 90% alcohol-water mixtures for 2 min, and 3% H₂O₂ for 15 min, respectively. The electricity was turned off upon reaching the boiling point. The sections were removed 5 min later and allowed to rest for 5 min. The procedure was repeated. The sections were removed after 5 min. Subsequently, the sections were treated with normal serum blocking solution and allowed to stand at 37°C for 30 min. Then, mouse anti-human antibody to TPX2 (1:1,000, ab32795, Abcam, Cambridge, MA, USA) was added as primary antibody and mouse anti-human antibody to immunoglobulin G (1:500, ab200699, Abcam) was added as isotype control. The sections were incubated overnight at 4°C and maintained at 37°C for 1 h. Sections were treated with the secondary goat anti-mouse polyclonal antibody (0.5 μg/mL, 1:500, ab2891, Abcam) and incubated for 30 min at 37°C. Horseradish peroxidase-labeled streptomyacin was added. The sections were stained using diaminobenzidine, washed under running water, and counterstained using hematoxylin for 1 min. Next, sections were dehydrated, cleared, sealed with neutral gum, and observed under a microscope.
Dual-Luciferase Reporter Gene Assay

Synthetic TPX2 3’ UTR gene fragment was incorporated into a pMIR-reporter plasmid (Huayueyang Biotechnology, Beijing, China). The complementary sequence mutation sites were designed based on the TPX2-WT sequence. Using restriction endonuclease digestions and ligations with the T4 DNA ligase, the target fragments were inserted into the pMIR-reporter plasmid, which were later co-transfected into HEK293T cells (Beinuo Biotechnology, Shanghai, China) using the miR-216b mimic. Luciferase activity was detected using a luciferase assay kit (K801-200, BioVision, Mountain View, CA, USA).

Cell Grouping

The cSCC cell line A431 was selected for the following experimental groups: the blank group (cells without transfection), the NC group (cells transfected with miR-216b NC plasmid), the miR-216b mimic group (cells transfected with miR-216b mimic), the miR-216b inhibitor group (cells transfected with miR-216b inhibitor), the si-TPX2 group, and the miR-216b inhibitor + si-TPX2 group. The cell cycle distribution was assessed by flow cytometry (Figure 6A). The comparisons of G0/G1 and G2/M cells among each group are shown in Figure 6B. The apoptotic cell rate was determined by flow cytometry (Figure 6C). The comparisons of apoptotic cell rate among each group are shown in Figure 6D. Data were expressed as mean ± standard deviation and data among multiple groups were compared by one-way ANOVA, followed by the Tukey’s post hoc test. *p < 0.05.
Table 2. Primer Sequences for qRT-PCR

| Gene    | Sequence (5'-3')                                   |
|---------|---------------------------------------------------|
| miR-216b| Forward: 5'-CCATGCAGGTGAGGCTTCGT-3'                |
|         | Reverse: 5'-GTATCGTGAGAGCACACATC-3'               |
| TPX2    | Forward: 5'-ATGGAACTGGAGGCTTTTTCT-3'              |
|         | Reverse: 5'-TGTTTGAACCTGGTTCAAGAGT-3'             |
| p53     | Forward: 5'-CAGCACATGGAGGAGTTGTG-3'                |
|         | Reverse: 5'-TCACCAATAACTCCACACGC-3'               |
| p21     | Forward: 5'-TGTCGGTCAAGACCCACGC-3'                |
|         | Reverse: 5'-AAAGTGAAGGGTTCATGGCTC-3'              |
| MDM2    | Forward: 5'-GAACATCGAGTCAGTTAATC-3'               |
|         | Reverse: 5'-CTCTGTCACATTAGGCTTCCT-3'              |
| PCNA    | Forward: 5'-CCACGGTATTTGGTTGAGGC-3'               |
|         | Reverse: 5'-CCACCCATGGTGGTTGAT-3'                 |
| bax     | Forward: 5'-GGTGAGCTTGCATGGTGG-3'                 |
|         | Reverse: 5'-CGTCTTCAGTACTCGATCC-3'                |
| bcl-2   | Forward: 5'-TGCGGCGACACAGTAC-3'                   |
|         | Reverse: 5'-TTAGAAGGCTTCAGAATATG-3'               |
| U6      | Forward: 5'-GCACCCGCTAAGGCTGAGAC-3'               |
|         | Reverse: 5'-TTGGTGAAGAGGCAGTGG-3'                 |
| GAPDH   | Forward: 5'-GGGTCGAGGATGGGCCTC-3'                 |
|         | Reverse: 5'-GGTTCAGTCTGCTATCC-3'                  |

TPX2 group (cells transfected with si-TPX2), and the miR-216b inhibitor + si-TPX2 group (cells transfected with miR-216b inhibitor + si-TPX2).

**qRT-PCR**

Total RNA was extracted from the experimental specimens using Trizol (Invitrogen, Carlsbad, CA, USA). RNA was reverse-transcribed into cDNA. PCR amplification was performed using a SYBR Premix Ex Taq II kit (Takara Biotechnology, Dalian, Liaoning, China) in an ABI 7500 PCR instrument. U6 was regarded as the internal reference for miR-216b while glyceraldehyde-3-phosphate dehydrogenase (GAPDH) served as loading control for other genes, and all primers (Table 2) were designed and synthesized by Wuhan BioJust Biological Engineering (Wuhan, Hubei, China). The 2^(-ΔΔCt) method was adopted for calculating the gene expression.

**Western Blot Analysis**

Total protein was isolated using the Radioimmunoprecipitation Assay Kit (R0010, Beijing Solabio Life Sciences, Beijing, China). Sodium dodecyl sulfate-polyacrylamide gel electrophoresis kit was used to prepare 10% separation gel and 5% concentrating gel samples. After electrophoresis, the protein was transferred onto a nitrocellulose membrane. The membrane was incubated with the following primary antibodies overnight at 4°C: rabbit polyclonal antibody to TPX2 (ab71816, 1:100, Abcam), p53 (ab32049, 1:100, Abcam), p21 (ab47300, 1:500, Abcam), MDM2 (ab38618, 1:1000, Abcam), bax (ab53154, 1:500, Abcam), bcl-2 (ab59348, 1:1000, Abcam), and PCNA (ab152112, 1:500, Abcam). The membrane was rinsed three times using Tris-buffered saline containing Tween 20 on the following day. The secondary rabbit polyclonal antibody (ab7312, Abcam) was added and incubated for 1 h. Developer (D-90G, Shanghai Yingdian Detection Equipment, Shanghai, China) was added, and images were acquired using the Bio-Rad gel imaging system (Beijing Thmoregan Biological Technology, Beijing, China). IPP7.0 software (Media Cybernetics, Bethesda, MD, USA) was adopted for quantitative analysis.

**MTT Assay**

Six groups of cSCC cells were prepared into a single cell suspension, which was stained using trypan blue with estimation of the living cells. Cells were inoculated in a 96-well plate (180 μL/well), and cultured at 37°C for 0 h, 24 h, 48 h, or 72 h in a 5% CO2 incubator. Next, 20 μL of 5% MTT reagent (Nanjing SenBélia Biological Technology, Nanjing, Jiangsu, China) was added and incubated at 37°C for 4 h in 5% CO2. The 96-well plate was subjected to 178 × g centrifugation for 10 min, after which 100 μL of dimethyl sulfoxide was added. Optical density (OD) at 570 nm was measured using a multi-function microplate reader (SAF-680T, Multiskan GO, Thermo, USA). The cell growth curve was plotted with the MTT treatment time as the horizontal axis and OD value as the longitudinal axis.

**Wound-Healing Assay**

Cells were inoculated in a 6-well plate and cultured using medium containing 10% fetal bovine serum overnight. Upon attaining 90% to 100% cell confluence, the wounds were created along the center of each well. Serum-free medium was added to continue culture. Images were acquired (at 0 h and 24 h) under an inverted microscope. Multi-fields were selected and photographed. IPP7.0 software (Media Cybernetics, Bethesda, MD, USA) was adopted to analyze the distance of cell migration.

**Transwell Assay**

Transwell chambers were coated with Matrigel (50 μL/micro pore) and incubated at 37°C for 60 min until the Matrigel solidified. Cells were resuspended and adjusted to a concentration of 1 x 10^5 cells/mL. Cell suspensions (200 μL) were added to the upper chamber coated with Matrigel, and 600 μL Roswell Park Memorial Institute 1640 medium was added to the lower chamber. After 24 h, cells on the upper surface of the chambers were removed. Paraformaldehyde (4%) was used to fix the cells for 15 min. The chamber was stained using 0.5% crystal violet for 15 min and photographed from five selected field views under an inverted microscope (XDS-800D, Shanghai Caikon Optical Instrument, Shanghai, China). Cells that passed through toward the bottom chamber were counted.

**Flow Cytometry**

The cells (1 x 10^5 cells/mL) were fixed using pre-cooled 75% ethanol at 4°C for 30 min, incubated with 100 μL of RNase A at
37°C for 30 min. After the addition of 400 μL propidium iodide (PI) staining buffer (P4170, Sigma-Aldrich Chemical Company, St. Louis, MO, USA) at 4°C, the samples were analyzed with a flow cytometer (Galileo, Beckman Coulter, S. Kraemer Boulevard Brea, CA, USA), using red fluorescence at 488 nm to detect cell-cycle distribution.

Annexin V-fluorescein isothiocyanate (FITC)/PI staining was performed in strict accordance with the provided instructions of the Annexin V-FITC cell apoptosis detection kit (K201-100, BioVision, Mountain View, CA, USA). Cells were resuspended in the Annexin V-FITC/PI staining solution, supplemented with 1 mL of N-2-hydroxyethylpiperazine-N-2-ethane sulfonic acid buffer solution, and incubated for 15 min. The fluorescence of FITC and PI was observed under 515 nm and 620 nm bandpass filters, respectively, following excitation at 488 nm. Apoptosis rate (%) = rate of early apoptosis + rate of late apoptosis.

Statistical Analysis
Statistical analyses were conducted using the SPSS 21.0 software (IBM, Armonk, NY, USA). Measurement data are expressed as mean ± standard deviation. Differences between two groups were compared by Student’s t test. Multiple groups were compared by one-way analysis of variance (ANOVA). A value of p < 0.05 was considered to be statistically significant.

AUTHOR CONTRIBUTIONS
C.F. and X.-J.W. participated in the conception and design of the study. H.-L.Z. and A.Z. collected the data. A.Z. and M.B. performed the analysis and interpretation of data. C.F., H.-L.Z., and X.-J.W. contributed to drafting the article. All authors have read and approved the final submitted manuscript.

CONFLICTS OF INTEREST
The authors declare no competing interests.

ACKNOWLEDGMENTS
We would like to show our sincere appreciation to our colleagues for technical help and stimulating discussion on this article.

REFERENCES
1. Ratushny, V., Gober, M.D., Hick, R., Ridky, T.W., and Seykora, J.T. (2012). From keratinocyte to cancer: the pathogenesis and modeling of cutaneous squamous cell carcinoma. J. Clin. Invest. 122, 464–472.
2. Green, A.C., and Olsen, C.M. (2017). Cutaneous squamous cell carcinoma: an epidemiological review. Br. J. Dermatol. 177, 373–381.
3. Liu, T., Lei, Z., Pan, Z., Chen, Y., Li, X., Mao, T., He, Q., and Fan, D. (2014). Genetic association between p53 codon 72 polymorphism and risk of cutaneous squamous cell carcinoma. Tumour Biol. 35, 3899–3903.
4. Ishitsuka, Y., Kawachi, Y., Taguchi, S., Maruyama, H., Nakamura, Y., Fujisawa, Y., Furuta, J., Nakamura, Y., Ishii, Y., and Otsuka, F. (2013). Pituitary tumor-transforming gene 1 as a proliferation marker lacking prognostic value in cutaneous squamous cell carcinoma. Exp. Dermatol. 22, 318–322.
5. Xu, N., Zhang, L., Meising, F., Harada, M., Heilborn, J., Homey, B., Grandé, D., Stähle, M., Sonkoly, E., and Pivarcsi, A. (2012). MicroRNA-125b down-regulates matrix metalloproteinase 13 and inhibits cutaneous squamous cell carcinoma cell proliferation, migration, and invasion. J. Biol. Chem. 287, 29899–29908.
6. Zhang, L., Jamaluddin, M.S., Weakley, S.M., Yao, Q., and Chen, C. (2011). Roles and mechanisms of microRNAs in pancreatic cancer. World J. Surg. 35, 1725–1731.
7. Allegra, A., Alonci, A., Campo, S., Penna, G., Petrunagaro, A., Gerace, D., and Musolin, C. (2012). Circulating microRNAs: new biomarkers in diagnosis, prognosis and treatment of cancer (review). Int. J. Oncol. 41, 1897–1912.
8. Deng, M., Tang, H., Zhou, Y., Zhou, M., Xiong, W., Zheng, Y., Ye, Q., Zeng, X., Liao, Q., Guo, X., et al. (2011). miR-216b suppresses tumor growth and invasion by targeting KRAS in nasopharyngeal carcinoma. J. Cell Sci. 124, 2997–3005.
9. Li, B., Qi, X.Q., Chen, X., Huang, X., Liu, G.Y., Chen, H.R., Huang, C.G., Luo, C., and Yu, Y.C. (2010). Expression of targeting protein for Xenopus kinesin-like protein 2 is associated with progression of human malignant astrocytoma. Brain Res. 1352, 200–207.
10. Chang, H., Wang, J., Tian, Y., Xu, J., Gou, X., and Cheng, J. (2012). The TPX2 gene is a promising diagnostic and therapeutic target for cervical cancer. Oncol. Rep. 27, 1353–1359.
11. Satow, R., Shitashige, M., Kainz, Y., Takeshita, F., Ojima, H., Jigami, T., Honda, K., Kosuge, T., Ochiya, T., Hiroshishi, S., and Yamada, T. (2010). Combined functional genome survey of therapeutic targets for hepatocellular carcinoma. Clin. Cancer Res. 16, 2518–2528.
12. Yan, L., Li, Q., Yang, J., and Qiao, B. (2018). TPX2–p53–GLIPR1 regulatory circuitry in cell proliferation, invasion, and tumor growth of bladder cancer. J. Cell. Biochem. 119, 1791–1803.
13. Nyriarena, C., Jouré-Mourin, A., Kartheuser, A., Camby, P., Plomteux, O., Detry, R., Dahan, K., and Sempoux, C. (2011). Distinctive patterns of p53 protein expression and microsatellite instability in human colorectal cancer. Hum. Pathol. 42, 1897–1910.
14. Muller, P.A., and Vousden, K.H. (2013). p53 mutations in cancer. Nat. Cell Biol. 15, 2–8.
15. Missero, C., and Antonini, D. (2014). CROSSTALK among p53 family members in cutaneous carcinoma. Exp. Dermatol. 23, 143–146.
16. Zhang, T.J., Wu, D.H., Zhou, J.D., Li, X., Zhang, W., Guo, H., Ma, J.C., Deng, Z., Lin, L., and Qian, J. (2018). Overexpression of miR-216b: Prognostic and predictive value in acute myeloid leukemia. J. Cell. Physiol. 233, 1274–1281.
17. Kim, S.Y., Lee, Y.H., and Bae, Y.S. (2012). MiR-186, miR-216b, miR-337-3p, and miR-760 cooperatively induce cellular senescence by targeting a subunit of protein kinase CKII in human colorectal cancer cells. Biochem. Biophys. Res. Commun. 429, 173–179.
18. Kwon, S., Dong, Z.M., and Wu, P.C. (2011). Sentinel lymph node biopsy for high-risk cutaneous squamous cell carcinoma: clinical experience and review of literature. World J. Surg. Oncol. 9, 80.
19. Zheng, L., Zhang, X., Yang, F., Zhu, J., Zhou, P., Yu, F., Hou, L., Xiao, L., He, Q., and Wang, B. (2014). Regulation of the P2X7R by microRNA-216b in human breast cancer. Biochem. Biophys. Res. Commun. 452, 197–204.
20. Liu, F.Y., Zhou, S.J., Deng, Y.L., Zhang, Z.Y., Zhang, E.L., Wu, Z.B., Huang, Z.Y., and Chen, X.P. (2015). MiR-216b is involved in pathogenesis and progression of hepatocellular carcinoma through HIFα-miR-216b-IGF2BP2 signaling pathway. Cell Death Dis. 6, e1676.
21. Yu, K., Zheng, X., Zhou, Z., Li, C., Zhang, J., Gao, J., Yao, Y., and Liu, Q. (2013). Recombinant human adenovirus-p53 injection induced apoptosis in hepatocellular carcinoma cell lines mediated by p53-Fbxw7 pathway, which controls c-Myc and cyclin E. PLoS ONE 8, e86574.
22. Yue, X., Zhang, C., Zhao, Y., Liu, J., Lin, A.W., Tan, V.M., Drake, J.M., Liu, L., Boettinger, M.N., Li, J., et al. (2017). Gain-of-function mutant p53 activates small GTPase Rac1 through SUMOylation to promote tumor progression. Genes Dev. 31, 1641–1654.
23. Zheng, T., Wang, J., Zhao, Y., Zhang, C., Lin, M., Wang, X., Yu, H., Liu, L., Feng, Z., and Hu, W. (2013). Spliced MDM2 isoforms promote mutant p53 accumulation and gain-of-function in tumorigenesis. Nat. Commun. 4, 2996.
(TLP) Disrupts the p53-MDM2 Interaction and Induces Long-lasting p53 Activation.
J. Biol. Chem. 292, 3201–3212.

25. Zhu, H.B., Yang, K., Xie, Y.Q., Lin, Y.W., Mao, Q.Q., and Xie, L.P. (2013). Silencing of
mutant p53 by siRNA induces cell cycle arrest and apoptosis in human bladder cancer
cells. World J. Surg. Oncol. 11, 22.

26. Khan, S., Chib, R., Shah, B.A., Wani, Z.A., Dhar, N., Mondhe, D.M., Lattoo, S., Jain,
S.K., Taneja, S.C., and Singh, J. (2011). A cyano analogue of boswellic acid induces
crosstalk between p53/PUMA/Bax and telomerase that stages the human papilloma-
virus type 18 positive HeLa cells to apoptotic death. Eur. J. Pharmacol. 660, 241–248.

27. de Queiroz, R.M., Madan, R., Chien, J., Dias, W.B., and Slawson, C. (2016). Changes
in O-Linked N-Acetylglucosamine (O-GlcNAc) Homeostasis Activate the p53
Pathway in Ovarian Cancer Cells. J. Biol. Chem. 291, 18897–18914.

28. Pascreau, G., Eckerdt, F., Lewellyn, A.L., Prigent, C., and Maller, J.L. (2009).
Phosphorylation of p53 is regulated by TPX2-Aurora A in xenopus oocytes. J. Biol.
Chem. 284, 5497–5505.

29. Liu, Y., Niu, Z., Lin, X., and Tian, Y. (2017). MiR-216b increases cisplatin sensitivity
in ovarian cancer cells by targeting PARP1. Cancer Gene Ther. 24, 208–214.

30. Wei, P., Zhang, N., Xu, Y., Li, X., Shi, D., Wang, Y., Li, D., and Cai, S. (2013). TPX2 is a
novel prognostic marker for the growth and metastasis of colon cancer. J. Transl.
Med. 11, 313.

31. Lambert, J.M., Moshfegh, A., Hainaut, P., Wiman, K.G., and Bykov, V.J. (2010).
Mutant p53 reactivation by PRIMA-1MET induces multiple signaling pathways
converging on apoptosis. Oncogene 29, 1329–1338.

32. Datta, A., Ghatak, D., Das, S., Banerjee, T., Paul, A., Butti, R., Gorain, M., Ghuwalewala,
S., Roychowdhury, A., Alam, S.K., et al. (2017). p53 gain-of-function mutations in-
crease Cdc7-dependent replication initiation. EMBO Rep. 18, 2030–2050.

33. Burrowes, D., Fangusaro, J.R., Nelson, P.C., Zhang, B., Wadhwani, N.R., Rozenfeld,
M.J., and Deng, J. (2017). Extended diffusion weighted magnetic resonance imaging
with two-compartment and anomalous diffusion models for differentiation of low-
grade and high-grade brain tumors in pediatric patients. Neuroradiology 59,
803–811.
